Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled 52-week study of two doses of EXPD-101 in COPD
CTR20262276Phase 2Active
- Sponsor
- Xinghao Pengbo
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of XH-S004 in chronic obstructive pulmonary disease (COPD), sponsored by Xinghao Pengbo. Started Aug 2026; status: active.
02
Drugs
XH-S004
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20262276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262276.